Analyst’s Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article. This article is intended to provide informational content and should not be viewed as an exhaustive an ...

相关文件明确，2026年1月1日起，所有医药机构都要实现药品追溯码全量采集上传。 目前，我国常见的药品追溯码有三种：一是"码上放心"追溯码，也就是最常见的20位条形码；二是部分 药品生产企业自行设定的编码标准，用于各自企业生产药品的追溯码，也以数字为主；三是国际GS1 （全球统一编码标识系统）编码，载体为二维码，多见于进口药品。全球已经有150多个国家和地区的 116个编码组织加入了GS1。 （来源：衢州日报） 转自：衢州日报 新华社北京12月25日电 （记者 彭韵佳） 作为每盒药品的"电子身份证"，药品追溯码具有唯一性，是打 击回流药的重要抓手。国家医保局最新消息显示，截至目前，生产流通端已累计采集药品追溯码约 440.8亿条，定点医药机构端采集药品追溯码达1014.81亿条。 一盒药品的追溯码，一般只有一次被扫码销售的记录，若重复出现多次，则存在假药、回流药或药品被 串换销售的可能。消费者可以通过国家医保局微信公众号"药品追溯信息查询"功能，扫描药盒上的药品 追溯码，获取详细的药品销售信息。 ...

The U.S. stock market is closed today, Thursday, December 25, 2025, in observance of the Christmas Day holiday, with trading on both the New York Stock Exchange (NYSE) and Nasdaq suspended for the entire day. However, the preceding trading session on Wednesday, December 24, 2025 (Christmas Eve), saw the Dow Jones Industrial Average (^DJI) advance 288.75 points (0.5961%) to 48,731.16, reaching a new record high in a shortened trading day. This upward movement occurred amidst light trading volumes as markets ...

Core Insights - Eli Lilly has achieved strong returns due to its advancements in weight management, positioning itself as a leader in this market [1] - The company is not resting on its laurels and continues to innovate, suggesting it may outpace competitors [1] Competitive Landscape - Novo Nordisk is the only significant competitor to Eli Lilly in the weight loss drug market, with its product Wegovy generating billions in sales [2] - Novo Nordisk is seeking label expansions and has requested FDA approval for a higher dose of semaglutide, the active ingredient in Wegovy [3][4] Product Performance - Eli Lilly's Zepbound has demonstrated superior average weight loss compared to Wegovy in clinical trials, generating $9.3 billion in revenue in the first nine months of 2025, while Wegovy generated approximately $9 billion [5] - Novo Nordisk's pipeline includes Amycretin, which is in phase 3 studies, but Eli Lilly's pipeline remains stronger with promising candidates like orforglipron and retatrutide [6][7] Market Position - Eli Lilly is clearly leading the weight loss market, with its current and future products positioning it ahead of competitors [8] - Novo Nordisk's CagriSema, which achieved a mean weight loss of 22.7%, is under regulatory review but still falls short compared to Eli Lilly's offerings [9]

SAN FRANCISCO, Dec. 25, 2025 (GLOBE NEWSWIRE) -- National shareholder rights law firm Hagens Berman is issuing a reminder to investors in Telix Pharmaceuticals Ltd. (NASDAQ: TLX) that the deadline to move the Court for appointment as lead plaintiff in the pending securities class action lawsuit is January 9, 2026. The lawsuit follows a series of regulatory setbacks—including an SEC subpoena and a devastating Complete Response Letter (CRL) from the FDA—that led to a sharp stock decline, with the final news t ...

NEW YORK, Dec. 25, 2025 (GLOBE NEWSWIRE) -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed against Telix Pharmaceuticals Limited (NASDAQ: TLX) and certain of its officers. This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Telix securities between February 21, 2025 and August 28, 2025 ...

Core Viewpoint - Dynavax Technologies Corp. is set to be acquired by Sanofi for $2.2 billion, leading to a significant increase in its stock price by 38.19% to $15.38 on the announcement day [1][5]. Group 1: Acquisition Details - Dynavax has officially entered into an agreement with Sanofi to acquire all outstanding shares at a price of $15.50 each, representing a premium of approximately 39% over its closing price on December 23 [2]. - The acquisition will enhance Sanofi's presence in adult immunization, particularly through Dynavax's adult hepatitis B vaccine, Heplisav-B, which offers a two-dose regimen that provides faster seroprotection compared to traditional three-dose vaccines [3]. Group 2: Vaccine Portfolio and Development - The acquisition includes Dynavax's shingles vaccine candidate (Z-1018), currently in phase 1/2 clinical development, along with other vaccine pipeline projects [4]. - Dynavax's CEO emphasized that joining Sanofi will leverage global scale and expertise to maximize the impact of their vaccine portfolio, addressing significant public health needs [5].

The U.S. stock market is closed today, Thursday, December 25, 2025, in observance of the Christmas Day holiday, providing a pause after a robust, record-setting session on Christmas Eve. Both the New York Stock Exchange (NYSE) and Nasdaq will remain fully shut, with normal trading operations set to resume on Friday, December 26, 2025. This holiday closure follows a shortened trading day on Wednesday, December 24, when major indexes closed higher, with the S&P 500 and Dow Jones Industrial Average reaching ne ...

Today, Novo commands a market capitalization of roughly $230.4 billion, underscoring its scale and influence in the global pharma landscape. Even so, the stock hasn’t had a smooth ride in 2025. Multiple factors, including soft demand for its blockbuster drugs and intensifying competition in the weight-loss space, have eroded investor confidence.Best known for its blockbuster weight-loss drugs Ozempic and Wegovy, Novo Nordisk is one of the world’s most influential healthcare companies, with a deep-rooted foc ...

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Telix Pharmaceuticals Limited due to allegations of violations of federal securities laws, specifically regarding misleading statements about the company's prostate cancer therapeutic candidates and supply chain quality [2][4]. Group 1: Legal Investigation and Class Action - The firm is encouraging investors who suffered losses in Telix between February 21, 2025, and August 28, 2025, to discuss their legal rights and options [1]. - A federal securities class action has been filed against Telix, with a deadline of January 9, 2026, for investors to seek the role of lead plaintiff [2]. - The lead plaintiff is defined as the investor with the largest financial interest in the relief sought, who will oversee the litigation on behalf of the class [7]. Group 2: Allegations Against Telix - The complaint alleges that Telix and its executives made false and misleading statements regarding the progress of prostate cancer therapeutic candidates and the quality of its supply chain [4]. - On July 22, 2025, Telix disclosed receiving a subpoena from the U.S. Securities and Exchange Commission, leading to a more than 13% drop in the price of its American Depositary Shares over two trading sessions [5]. - On August 28, 2025, Telix revealed it received a Complete Response Letter from the U.S. Food and Drug Administration for its product TLX250-CDx, which identified deficiencies in the Chemistry, Manufacturing, and Controls package, resulting in a more than 21% decline in share price over two trading sessions [6].